Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vyne Therapeutics : Says Austin Institute for Clinical Research Launches Study on Acne Combination Therapy

07/19/2021 | 10:31am EDT


ę MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
09/20VYNE THERAPEUTICS : to Present at the Cantor Fitzgerald Investment Conference
AQ
09/08VYNE THERAPEUTICS : to Present at the H.C. Wainwright Annual Investment Conference
AQ
09/03VYNE THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/18INSIDER TRENDS : Selling By Insiders Lingers at VYNE Therapeutics
MT
08/17INSIDER TRENDS : Insider Sales Add to 90-Day Trend at VYNE Therapeutics
MT
08/16INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at VYNE Therapeutics
MT
08/13VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keep..
MT
08/12VYNE THERAPEUTICS : Explanatory Note (Form 8-K)
PU
08/12VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial Statements ..
AQ
08/12VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 18,2 M - -
Net income 2021 -70,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,14x
Yield 2021 -
Capitalization 78,3 M 78,3 M -
Capi. / Sales 2021 4,29x
Capi. / Sales 2022 10,9x
Nbr of Employees 106
Free-Float 87,1%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,52 $
Average target price 6,67 $
Spread / Average Target 339%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-75.95%78
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582